
News|Articles|November 27, 2023
The value of Innovative Medicine: The clinical and economic impact of the first gene therapy for hemophilia B
Advertisement
Content provided by CSL Behring. Copyright 2023 and published by MJH Life Sciences®. No portion of this program may be reproduced or transmitted in any form, by any means, without the prior written permission of MJH Life Sciences. The views and opinions expressed in this material do not necessarily reflect the views and opinions of MJH Life Sciences, or Managed Healthcare Executive®.
Advertorial: 
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
HPV Vaccine Still Highly Effective 17 Years After Introduction
2
Nonfactor Therapies for Hemophilia: Current Evidence, Clinical Relevance and Cost Considerations
3
Nonfactor agents for hemophilia prophylaxis: A Q&A with Steven Pipe, M.D.
4
Payers Are Bracing for the Specialty Trend of the Future | AMCP Nexus 2025
5

















































